Your browser is no longer supported. Please, upgrade your browser.
Settings
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.75 Insider Own5.70% Shs Outstand70.84M Perf Week-5.12%
Market Cap8.43B Forward P/E- EPS next Y-3.15 Insider Trans-5.84% Shs Float62.90M Perf Month-14.24%
Income-245.00M PEG- EPS next Q-1.04 Inst Own93.10% Short Float14.88% Perf Quarter-6.73%
Sales273.90M P/S30.79 EPS this Y84.30% Inst Trans1.70% Short Ratio8.20 Perf Half Y31.06%
Book/sh9.66 P/B12.32 EPS next Y28.40% ROA-19.50% Target Price195.14 Perf Year116.28%
Cash/sh11.19 P/C10.64 EPS next 5Y-0.20% ROE-33.70% 52W Range50.68 - 176.50 Perf YTD113.95%
Dividend- P/FCF- EPS past 5Y30.00% ROI-14.20% 52W High-32.56% Beta1.76
Dividend %- Quick Ratio7.80 Sales past 5Y32.90% Gross Margin91.00% 52W Low134.89% ATR8.89
Employees255 Current Ratio8.80 Sales Q/Q70.70% Oper. Margin-83.00% RSI (14)41.35 Volatility7.72% 7.10%
OptionableYes Debt/Eq0.65 EPS Q/Q-48.70% Profit Margin-89.50% Rel Volume0.62 Prev Close118.96
ShortableYes LT Debt/Eq0.65 EarningsOct 24 AMC Payout- Avg Volume1.14M Price119.04
Recom1.70 SMA20-7.82% SMA50-13.87% SMA2009.02% Volume706,021 Change0.07%
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
May-07-18Reiterated Needham Buy $75 → $109
May-07-18Reiterated H.C. Wainwright Buy $90 → $96
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-13-18Reiterated H.C. Wainwright Buy $75 → $92
Jan-22-18Initiated RBC Capital Mkts Outperform
Jan-04-18Initiated Janney Buy $75
Dec-01-17Initiated H.C. Wainwright Buy $75
Oct-06-17Resumed Goldman Buy $71
Oct-02-17Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-16-18 07:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics ACCESSWIRE
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-08-18 07:13PM  Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock GlobeNewswire -7.68%
Nov-07-18 04:21PM  Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock GlobeNewswire +5.02%
Nov-06-18 10:13AM  Hedge Funds Just Stormed Into This Red-Hot Biotech Company Insider Monkey
08:43AM  Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options Zacks
Nov-05-18 10:17AM  Weekly CEO Buys Highlight GuruFocus.com
Nov-02-18 12:13PM  Weekly CFO Sells Highlight GuruFocus.com
08:30AM  Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference GlobeNewswire
Oct-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.50%
08:00AM  Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics ACCESSWIRE
Oct-30-18 09:15PM  Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of Shares GuruFocus.com +6.46%
08:00AM  Report: Exploring Fundamental Drivers Behind Sarepta Therapeutics, Reinsurance Group of America, Illinois Tool Works, ATN International, Morningstar, and Hubbell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-29-18 12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
Oct-26-18 08:15AM  Edited Transcript of SRPT earnings conference call or presentation 24-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-25-18 11:06AM  Sarepta (SRPT) Q3 Earnings & Sales Miss, Exondys 51 Sales Up Zacks
Oct-24-18 07:00PM  Sarepta Therapeutics (SRPT) Reports Q3 Loss, Lags Revenue Estimates Zacks -8.40%
05:53PM  Sarepta Therapeutics: 3Q Earnings Snapshot Associated Press
04:06PM  Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
08:22AM  Q3 Earnings Preview For Sarepta Therapeutics Benzinga
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-18-18 04:30PM  Sarepta Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Corporate Developments on October 24, 2018 GlobeNewswire
Oct-17-18 11:40AM  Duchenne biotech Sarepta to open gene therapy facility in Ohio American City Business Journals
10:32AM  Sarepta Therapeutics (SRPT) Q3 Earnings Preview: What to Expect Zacks
10:00AM  Sarepta Announces Agreement With Lysogene for Gene Therapy Zacks
Oct-16-18 04:12PM  Boston biopharma commercializing Nationwide Children's gene therapies to add Columbus office, 100 jobs American City Business Journals +5.51%
Oct-15-18 08:00AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Amicus Therapeutics ACCESSWIRE
08:00AM  Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate GlobeNewswire
Oct-12-18 01:46PM  Are Sarepta Therapeutics Incs (NASDAQ:SRPT) Interest Costs Too High? Simply Wall St. +6.96%
Oct-11-18 02:55PM  Sarepta CEO charts path forward on Duchenne drug amid stock slide American City Business Journals
11:11AM  Square Continues to See Extreme Pressure TheStreet.com
10:10AM  Here's Why Sarepta Therapeutics Jumped 17% in September Motley Fool
Oct-08-18 08:30AM  Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies GlobeNewswire
Oct-05-18 08:30AM  Sarepta Announces Agreement with Nationwide Childrens Hospital for Rights to its Gene Therapy Program to Treat Charcot-Marie-Tooth (CMT) Neuropathy, Globally the Most Common Inherited Neuromuscular Disorder GlobeNewswire -5.47%
Oct-04-18 08:00AM  Today's Research Reports on Trending Tickers: Tesaro and Sarepta Therapeutics ACCESSWIRE
07:59AM  The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut Benzinga
Oct-03-18 05:15PM  Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
Oct-02-18 01:18PM  Overall Market Breadth Remains Negative TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE
Oct-01-18 10:28AM  5 Best Biotech Stocks to Buy In October Zacks -7.89%
Sep-28-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-18 08:30AM  Sarepta Therapeutics and Jerry R. Mendell, M.D. from Nationwide Childrens Hospital to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society GlobeNewswire
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
Sep-25-18 10:44AM  FDA Lifts Clinical Hold on Sarepta's DMD Gene Therapy Program Zacks
Sep-24-18 04:43PM  CHMP Reconfirms Negative Opinion for Sarepta's Exondys Zacks
08:19AM  Sarepta stock rises after FDA lifts clinical hold on gene therapy program MarketWatch
07:00AM  Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program GlobeNewswire
Sep-21-18 12:01PM  Sarepta investors, analysts shrug off E.U. setback for Duchenne drug American City Business Journals
06:48AM  Sarepta expected, but is disappointed by European regulators decision on DMD treatment MarketWatch
06:30AM  Sarepta Receives Negative CHMP Re-examination Opinion for Eteplirsen GlobeNewswire
Sep-12-18 01:10PM  Corrective Action in This Market Is Often Quite Hidden TheStreet.com +5.07%
Sep-11-18 07:43PM  Why Sarepta Therapeutics, Inc. Stock Jumped 18.8% Higher in August Motley Fool
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Sep-07-18 05:05PM  Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy CNBC
03:34PM  Sarepta Therapeutics CEO on soaring stock and drug develo... CNBC Videos
09:30AM  Why Is Sarepta Therapeutics (SRPT) Up 6.4% Since Last Earnings Report? Zacks
09:15AM  Today's Bell Ringer, September 7, 2018 CNBC Videos
08:30AM  Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony GlobeNewswire
Sep-06-18 02:47PM  Credit Suisse Joins Consensus To Prescribe Sarepta Benzinga
Sep-04-18 01:51PM  The Market Is Finally Pulling Back TheStreet.com
08:30AM  Sarepta Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
Aug-31-18 06:36PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 02:00PM  CRISPR without consequences? Startup's drug shows promise in animal study American City Business Journals
01:38PM  A Lesson to Learn From Thursday's Market Action TheStreet.com
12:47PM  Scholar Rock stock tumbles 11% as Pfizer discontinues similar medication MarketWatch
08:28AM  Pfizer stops developing therapy for the rare disease Duchenne muscular dystrophy MarketWatch
08:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Aug-29-18 05:12PM  Time to Take Some Profits in Sarepta Therapeutics Stock InvestorPlace
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
Aug-22-18 12:11AM  Edited Transcript of SRPT earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-20-18 11:50AM  Weekly CEO Buys Highlight GuruFocus.com
08:30AM  Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program GlobeNewswire
Aug-17-18 07:45AM  Jim Cramer Weighs In On NuStar Energy, Royal Dutch Shell, United Rentals And More Benzinga
Aug-16-18 07:00AM  Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musks Tail Market Exclusive
Aug-15-18 02:01PM  Prepare For the Worst but Stay Positive TheStreet.com
Aug-14-18 02:05PM  Little Fear of Missing Out as Stocks Hold Gains TheStreet.com
Aug-13-18 12:36PM  Overly Aggressive Dip Buyers Finally Trapped TheStreet.com
Aug-10-18 03:17PM  GlycoMimetics Stock Has Substantial Upside InvestorPlace
07:52AM  Is Sarepta Therapeutics Stock a Bargain? Motley Fool
Aug-09-18 05:20PM  Why Sarepta Therapeutics, Inc. Stock Surged Today Motley Fool +9.87%
09:35AM  Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales Zacks
08:40AM  Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options Zacks
Aug-08-18 05:50PM  Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:47PM  Sarepta Therapeutics: 2Q Earnings Snapshot Associated Press
04:02PM  Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
04:01PM  Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools GlobeNewswire
02:30PM  Sarepta Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 10:03AM  Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate Benzinga
Jul-31-18 06:00PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities ACCESSWIRE
Jul-26-18 10:30AM  Sarepta's Clinical Hold Could Be A Solid Biosciences Catalyst, Says Bullish Chardan Analyst Benzinga
09:00AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
08:20AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Global Blood Therapeutics ACCESSWIRE
Jul-25-18 04:44PM  Sarepta stock drops after Muscular Dystrophy study halted by FDA MarketWatch
04:34PM  Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events GlobeNewswire
Jul-23-18 02:24PM  Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sareptas RNA-Targeted Technology Platforms Business Wire
Jul-20-18 08:30AM  Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018 GlobeNewswire
Jul-16-18 02:53PM  The 5 Best Growth Stocks of 2018 (So Far) Motley Fool
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jul-08-18 08:30PM  [$$] Patients Win With More Access to Treatments The Wall Street Journal
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorNov 01Option Exercise8.946,66759,60316,751Nov 02 06:01 PM
Wigzell Hans Lennart RudolfDirectorNov 01Sale140.506,667936,71410,084Nov 02 06:01 PM
BEHRENS M KATHLEENDirectorOct 31Option Exercise3.9610,00039,600126,534Nov 02 06:00 PM
BEHRENS M KATHLEENDirectorOct 31Sale131.7110,0001,317,100116,534Nov 02 06:00 PM
INGRAM DOUGLAS SPresident & CEOOct 30Buy120.3916,6952,009,872415,945Oct 30 07:05 PM
Mahatme SandeshEVP, CFO & CBOOct 24Option Exercise14.8889,4001,330,389128,185Oct 26 06:43 PM
Mahatme SandeshEVP, CFO & CBOOct 24Sale127.74107,52413,735,11620,661Oct 26 06:43 PM
INGRAM DOUGLAS SPresident & CEOAug 15Buy125.2616,0002,004,211399,250Aug 16 07:30 AM
Howton David TSVP, General CounselJul 16Option Exercise13.8550,000692,69172,719Jul 17 06:01 PM
Howton David TSVP, General CounselJul 16Sale136.4650,0006,823,00034,871Jul 17 06:01 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Option Exercise13.7833,782465,41540,690Jul 11 06:05 PM
Cumbo AlexanderSVP, Chief Commercial OfficerJul 09Sale137.3233,7824,638,94428,766Jul 11 06:05 PM
Barry RichardDirectorJun 27Sale130.3475,0009,775,5003,170,432Jun 29 06:01 PM
Ruff ShamimSVP, Chief Regulatory AffairsMar 15Option Exercise23.932,50059,81329,465Mar 16 06:13 PM
Howton David TSVP, General CounselMar 15Option Exercise22.152,50055,38231,727Mar 16 06:12 PM
Cumbo AlexanderSVP, Chief Commercial OfficerMar 15Option Exercise20.642,50051,60025,767Mar 16 06:10 PM
Mahatme SandeshEVP, CFO & CBOMar 15Option Exercise23.852,50059,62543,395Mar 16 06:08 PM
Wigzell Hans Lennart RudolfDirectorNov 30Option Exercise7.386,66749,20213,333Dec 04 08:00 PM
Wigzell Hans Lennart RudolfDirectorNov 30Sale55.896,667372,6196,666Dec 04 08:00 PM